Hanninen, M., P. Venner, and S. North. “A Rapid PSA Half-Life Following Docetaxel Chemotherapy Is Associated With Improved Survival in Hormone Refractory Prostate Cancer”. Canadian Urological Association Journal, vol. 3, no. 5, May 2013, pp. 369-74, doi:10.5489/cuaj.1145.